OSLO, October 12 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision medicine utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces that CEO Dr Per Walday
will be participating in a panel of international experts discussing "The
Promise and Challenges of Ultrasound-Mediated Delivery" at the Partnership
Opportunities in Drug Delivery Conference in Boston, USA on October 17. 

The panel will be moderated by Dr Vincent Ling, Senior Director for External
Innovation at Takeda and the panelists will share results and future views on
the applications of ultrasound mediated drug delivery, challenges to overcome
for translation into the clinic, and potential directions for the technology. 

This is a good opportunity to showcase the unique ACT technology to a leading
group of pharma and biotech executives focusing on enhancing and targeting drug
and precision medicine delivery.
The event will take place on October 17, 15:15 EST (21:15 CEST).


About PODD (Partnership Opportunities in Drug Delivery)
Pharma, biotech and the drug delivery industries gather annually at PODD to
assess delivery needs, latest trends and information on deals and learn about a
wide range of innovative drug delivery technologies that could improve the
delivery of various types of drugs. This can include proteins, peptides,
oligonucleotides, biologics, and small molecules and more. PODD provides
business development opportunities through organized networking and a partnering
tool for new, emerging and established collaborations.

https://theconferenceforum.org/conferences/partners-in-drug-delivery/overview/

For more information, please contact: 
Per Walday 
CEO EXACT Therapeutics 
Email: per.walday@exact-tx.com 

About EXACT-Tx: 
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

About ACT® 
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration. 
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (CNS, immunotherapy) and product classes. 

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.